OPK, a multinational biopharmaceutical and diagnostics company ... became clinically available for patients with advanced solid tumors. This liquid biopsy test enables oncologists to perform ...

OPK believes that gene-based antibody expression ... approval of its in vitro diagnostic TruSight Oncology Comprehensive test and its first two companion diagnostic indications.

OPK delivered earnings per share (EPS ... This was primarily due to lower clinical test volume, principally resulting from the sale of certain BioReference assets. This compares to our projection ...